(Alliance News) - Omega Diagnostics Group PLC on Thursday said Mologic Ltd has received a CE mark for its professional-use Covid-19 rapid antigen test.
Back in June, the London-listed medical diagnostics company signed a material transfer agreement with Mologic providing access to raw materials and know-how to manufacture the lateral flow antigen test.
The test will provide healthcare professionals an accurate detection of the nucleoprotein of the SARS-CoV-2 virus in respiratory swabs.
As announced at its interim results in November, Omega has now established its technology transfer team and looks forward to giving an update in the new year on how the technology transfer and CE Mark is going, so the company can sell the rapid test under Omega's Visitect brand.
Omega Chief Executive Colin King said: "We welcome the news that Mologic has received CE Mark for its Rapid Antigen Test, and are excited about completing the technology transfer and CE Marking in the New Year."
Shares in Omega Diagnostics closed up 18% at 62.00 pence in London on Thursday.
By Lucy Heming; lucyheming@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
